A Phase 4 interventional study of In this study, morphine administration, which is routinely and frequently used in our operating room for patients undergoing CABG, was applied as an additional intervention in Cardiac Surgery Patient, Postoperative Pain and Pain After Surgery, sponsored by Istanbul University - Cerrahpasa. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Istanbul University - Cerrahpasa · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Pain, Postoperative by Istanbul University - Cerrahpasa — 4 open to participants now, 5 under way, none of them phase 3. Pain, Postoperative · Istanbul University - Cerrahpasa.
Among the 18 studies in Pain, Postoperative by Istanbul University - Cerrahpasa, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is one of 6 that started in 2026, is one of 2 in phase 4, and was the 16th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →4 of the 18 studies in Pain, Postoperative by Istanbul University - Cerrahpasa are open now, in 1 country. Recruiting first, the newest first:
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–65
Istanbul University - Cerrahpasa
Ages 18+
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 6 mo–12 yrs
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 1–18
By country, each count listing its studies:
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 6 started in 2026.
This study's enrollment of 80 is close to the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 65 across the 12 interventional studies, 94 across the 6 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
Istanbul University - Cerrahpasa is the lead sponsor of 702 studies on the registry; 212 are open to participants now.
2 of the studies in Pain, Postoperative by Istanbul University - Cerrahpasa that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07322900Istanbul University - CerrahpasaEvaluation of Chronic Postsurgical Pain Risk in Patients Undergoing CIED Implantation Using an AID Support System | 2026-12-01 |
| NCT07711496Istanbul University - CerrahpasaRetrolaminar Plane Block Versus Anterior Quadratus Lumborum Block in Pediatric Urogenital Surgery | 2027-07-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Pain, Postoperative by Istanbul University - Cerrahpasa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Ethics committee approval was obtained for this study, which was planned as a prospective, randomized, controlled, single-center trial to be conducted in patients undergoing coronary artery bypass grafting (CABG) surgery between December 2025 and March 2026.
Patients eligible for inclusion were randomized into two groups at a 1:1 ratio using a random number list generated via the random.org website. Randomization was performed by an independent investigator who was not involved in the study procedures. The allocation sequence was placed into sequentially numbered, opaque, sealed envelopes. Upon enrollment of each patient, the next numbered envelope was opened to determine group assignment.
Patients who did not complete the study protocol or did not receive the allocated medication were excluded from the analysis, and a per-protocol analysis approach was applied. The randomization list was kept confidential and was accessible only to authorized statistical personnel. Patients were followed in two groups: the Control Group (Group C) and the Morphine Group (Group M).
All procedures were performed at the Istanbul University-Cerrahpaşa Cardiology Institute. After obtaining written informed consent, all patients were transferred to the operating room, where an 18G intravenous cannula was inserted, followed by premedication with midazolam 0.03 mg/kg (IV).
Standard monitoring included 5-lead electrocardiography (ECG), heart rate measurement, invasive arterial blood pressure monitoring, and peripheral oxygen saturation assessment. Anesthesia induction was standardized for all patients using midazolam 0.15 mg/kg, fentanyl 10 µg/kg, and rocuronium 0.6 mg/kg (IV). Orotracheal intubation was performed using an endotracheal tube of appropriate size according to the patient's age and sex.
Following intubation, mechanical ventilation was initiated and adjusted to maintain end-tidal carbon dioxide (EtCO₂) levels between 35 and 45 mmHg. Anesthesia maintenance was achieved using a total intravenous anesthesia (TIVA) technique with continuous infusions of propofol (1-10 mg/kg/h), fentanyl (2-4 µg/kg/h), and rocuronium (20 mg/h), targeting a bispectral index (BIS) value between 40 and 60. Prior to surgical incision, patients in the Morphine Group (Group M) received 5 mg intravenous morphine, administered with careful consideration of their hemodynamic status.
During surgery, all patients were placed on cardiopulmonary bypass (CPB). After completion of graft anastomoses and stabilization of vital signs, patients were weaned from CPB. At this stage, patients in Group M received an additional 5 mg intravenous morphine. In contrast, patients in the Control Group (Group K) continued to receive perioperative fentanyl infusion.
Postoperatively, patients were transferred to the intensive care unit (ICU) while intubated and mechanically ventilated. Extubation was performed according to clinical criteria. In the ICU, all patients received intravenous paracetamol 1000 mg every 6 hours and tramadol 100 mg intravenously. Pain intensity was assessed using the Numerical Rating Scale (NRS) / Visual Analog Scale (VAS). If the pain score exceeded 4, 3 mg intravenous morphine was administered, and total morphine consumption was recorded.
Preoperative variables collected included age, sex, height, weight, body mass index (BMI), and American Society of Anesthesiologists Physical Status (ASA PS) classification. Intraoperative variables included administered drug doses, duration of surgery, cardiopulmonary bypass time, and total anesthesia duration.
In the postoperative period, the duration of mechanical ventilation in the intensive care unit (ICU), the presence of nausea and vomiting, postoperative ileus, and respiratory depression will be recorded. In addition, pain intensity at the thoracic tube insertion site, sternum, and saphenous vein graft incision will be assessed at the 1st, 2nd, 4th, 8th, and 24th hours following extubation using the Numerical Rating Scale (NRS) / Visual Analog Scale (VAS). All pain assessments will be performed and recorded by a blinded observer. Pain associated with the urinary catheter will also be evaluated using the NRS.
Prolonged postoperative ileus will be defined as the presence of abdominal distension and absence of bowel sounds in a patient without mechanical intestinal obstruction who experiences nausea or vomiting and fails to pass flatus or stool for more than three postoperative days. The severity and frequency of postoperative nausea and vomiting (PONV) will be assessed. Respiratory depression will be defined as a suppressed ventilatory response to hypercapnia or hypoxemia.
Pain intensity at the thoracic tube insertion site, sternum, and saphenous vein graft incision will be assessed at the 1st, 2nd, 4th, 8th, and 24th hours following extubation using the Numerical Rating Scale (NRS) / Visual Analog Scale (VAS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this group received a standard fentanyl infusion during the entire CABG procedure until they were transferred out of the operating room."
Patients in this group received 5 mg of morphine prior to the initiation of the surgical procedure and an additional 5 mg at the time of separation from cardiopulmonary bypass.
Drug: In this study, morphine administration, which is routinely and frequently used in our operating room for patients undergoing CABG, was applied as an additional intervention
Unlike previous studies, this study aims to evaluate the postoperative effects of morphine administered intraoperatively rather than postoperative morphine administration
VAS Level
Pain scores at the thoracic tube insertion site, sternum, and saphenous graft incision will be assessed using a visual analog scale (VAS) by a blinded observer. The VAS consists of a 10-cm horizontal line anchored by two descriptors: "no pain" at the left end (0) and "worst imaginable pain" at the right end (10). Patients are asked to mark the point on the line that best represents their perceived level of pain at the time of assessment. The distance from the left end of the line to the patient's mark is measured in centimeters and recorded as the VAS score, ranging from 0 to 10. 0: No pain 1-3: Mild pain 4-6: Moderate pain 7-10: Severe pain
Time frame: 1st, 2nd, 4th, 8th, and 24th hours after extubation.
PONV
The secondary objective is to assess, the incidence of nausea and vomiting (PONV)(side effect of morphine). The severity and frequency of PONV will be assessed. PONV will be graded as follows: None: No nausea, Mild nausea, a single episode of vomiting, nausea triggered by external stim, Moderate: Two episodes of vomiting, nausea without external stimulus, and need for a single dose of antiemetic, Severe nausea, more than two episodes of vomiting, and requirement for multiple doses of antiemetics
Time frame: 1st, 2nd, 4th, 8th, and 24th hours after extubation
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Jun 2026, 4 months.
Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 4 months is below that.
Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion May 2026 → Jun 2026 and completion May 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul University - Cerrahpasa →